Journal of Thrombosis and Haemostasis

Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men
pp. 1605-1611(7)
Authors: WANNAMETHEE, S. G.; WHINCUP, P. H.; SHAPER, A. G.; RUMLEY, A.; LENNON, L.; LOWE, G. D. O.

Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction
pp. 1612-1618(7)
Authors: HEESTERMANS, A. A. C. M.; VAN WERKUM, J. W.; HAMM, C.; DILL, T.; GOSSELINK, A. T. M.; DE BOER, M. J.; VAN HOUWELINGEN, G.; HOORNTJE, J. C. A.; KOOPMANS, P. C.; TEN BERG, J. M.; VAN T HOF, A. W. J.

The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios
pp. 1619-1628(10)
Authors: MEIJER, K.; SCHULMAN, S.

Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency
pp. 1629-1632(4)
Authors: SCHMID, P.; BRODMANN, D.; ODERMATT, Y.; FISCHER, A. G.; WUILLEMIN, W. A.

Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism
pp. 1633-1638(6)
Authors: BISS, T. T.; BRANDÃO, L. R.; KAHR, W. H. A.; CHAN, A. K. C.; WILLIAMS, S.

Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study
pp. 1639-1648(10)
Authors: LUTSEY, P. L.; FOLSOM, A. R.; HECKBERT, S. R.; CUSHMAN, M.

Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA
pp. 1649-1655(7)
Authors: SCHNEITER, S.; COLUCCI, G.; SULZER, I.; BARIZZI, G.; LÄMMLE, B.; ALBERIO, L.

Factor IX mutants with enhanced catalytic activity
pp. 1656-1662(7)
Authors: HARTMANN, R.; DOCKAL, M.; KAMMLANDER, W.; PANHOLZER, E.; NICOLAES, G. A.; FIEDLER, C.; ROSING, J.; SCHEIFLINGER, F.

Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine
pp. 1663-1671(9)
Authors: HAWKSWORTH, J. S.; ELSTER, E. A.; FRYER, D.; SHEPPARD, F.; MORTHOLE, V.; KRISHNAMURTHY, G.; TOMORI, T.; BROWN, T. S.; TADAKI, D. K.

An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution
pp. 1672-1679(8)
Authors: BERBER, E.; JAMES, P. D.; HOUGH, C.; LILLICRAP, D.

Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction
pp. 1680-1687(8)
Authors: SZANTO, T.; VANHOORELBEKE, K.; TOTH, G.; VANDENBULCKE, A.; TOTH, J.; NOPPE, W.; DECKMYN, H.; HARSFALVI, J.

Molecular basis of thrombomodulin activation of slow thrombin
pp. 1688-1695(8)
Authors: ADAMS, T. E.; LI, W.; HUNTINGTON, J. A.

Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X
pp. 1696-1702(7)
Authors: YANG, L.; MANITHODY, C.; REZAIE, A. R.

IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
pp. 1703-1710(8)
Authors: FERRARI, S.; MUDDE, G. C.; RIEGER, M.; VEYRADIER, A.; KREMER HOVINGA, J. A.; SCHEIFLINGER, F.

Platelet glycoprotein VI as a mediator of metastasis
pp. 1711-1712(2)
Author: FARNDALE, R. W.

Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models
pp. 1713-1717(5)
Authors: JAIN, S.; RUSSELL, S.; WARE, J.

Proteomic analysis of integrin αIIbβ3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions
pp. 1718-1726(9)
Authors: SENIS, Y. A.; ANTROBUS, R.; SEVERIN, S.; PARGUIÑA, A. F.; ROSA, I.; ZITZMANN, N.; WATSON, S. P.; GARCÍA, A.

Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo
pp. 1727-1735(9)
Authors: STRUTHMANN, L.; HELLWIG, N.; PIRCHER, J.; SOHN, H.-Y.; BUERKLE, M. A.; KLAUSS, V.; MANNELL, H.; POHL, U.; KRÖTZ, F.

Screening computer-assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs
pp. 1736-1736(1)
Authors: POLLER, L.; ROBERTS, C.; IBRAHIM, S.; KEOWN, M.; AGENO, W.; VAN DEN BESSELAAR, A. M. H. P.; FITZMAURICE, D.; HARENBERG, J.; KITCHEN, S.; LOWE, G.; MOIA, M.; PALARETI, G.; TRIPODI, A.; TURPIE, A. G. G.; JESPERSEN, J.

Update of the guidelines for lupus anticoagulant detection
pp. 1737-1740(4)
Authors: PENGO, V.; TRIPODI, A.; REBER, G.; RAND, J. H.; ORTEL, T. L.; GALLI, M.; DE GROOT, P. G.

Total knee arthroplasty in hemophilic arthropathy: efficiency of clotting factor usage in multijoint procedures
pp. 1741-1743(3)
Authors: SCHILD, F. J. A.; MAUSER-BUNSCHOTEN, E. P.; VERBOUT, A. J.; VAN RINSUM, A. C.; ROOSENDAAL, G.

Replication of findings on the association of genetic variation in 24 hemostasis genes and risk of incident venous thrombosis
pp. 1743-1746(4)
Authors: SMITH, N. L.; WIGGINS, K. L.; REINER, A. P.; LANGE, L. A.; CUSHMAN, M.; HECKBERT, S. R.; LUMLEY, T.; RICE, K. M.; FOLSOM, A. R.; PSATY, B. M.

CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
pp. 1747-1749(3)
Authors: ALEIL, B.; LÉON, C.; CAZENAVE, J.-P.; GACHET, C.

von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size
pp. 1749-1752(4)
Authors: JIN, S.-Y.; SKIPWITH, C. G.; SHANG, D.; ZHENG, X. L.

Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA: a rebuttal
pp. 1753-1755(3)
Authors: KÖCHLI, A.

Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA: reply to a rebuttal
pp. 1755-1756(2)
Authors: COLUCCI, G.; LÄMMLE, B.; ALBERIO, L.

Join ISTH
pp. 1757-1757(1)

Corrigendum
pp. 1758-1758(1)